Cervical cancer
Conditions
Interventions
Test group:Anlotinib with chemoradiotherapy
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up; 2. Age >= 18 years old (calculated on the day of signing informed consent); 3. Pathologically or histologically confirmed cervical cancer (squamous, adenocarcinoma or adenosquamous) with measurable lesions; 4. Initially diagnosed IVB stage (according to FIGO 2018 staging); 5. ECOG score is 0~2 points; 6. Major organ function meets protocol criteria within 7 days before treatment.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with contraindications to antiangiogenic drugs: 3. Received radiotherapy in the past; 4. Those with high blood pressure that cannot be controlled by treatment; 5. Urine routine shows protein positive++; 6. There are many factors that affect oral drugs (inability to swallow, chronic diarrhea and intestinal obstruction, etc.); 7. Abnormal coagulation function and bleeding tendency: such as active ulcer foci, fecal occult blood (++), etc.; 8. Grade 3-4 cardiac insufficiency (New York cardiac function classification); 9. Patients with severe hepatic and renal insufficiency (grade 4); 10. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study; 11. Expected survival less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, OS;Progression free survival, PFS;Disease control rate, DCR; | — |
Countries
China
Contacts
Public ContactShoumin Bai
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Outcome results
None listed